H.C. Wainwright raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $7 from $1.50 and keeps a Buy rating on the shares following the Q1 report. The company is on track to complete enrollment in the Phase 3 4WARD study evaluating mavorixafor with or without constant doses of G-CSF in congenital, idiopathic, and autoimmune chronic neutropenia by Q4, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue